| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ove Bergersen, Kine Østnes Hanssen, Terje Vassko. Anaerobic treatment of sewage sludge containing selective serotonin reuptake inhibitors. Bioresource technology. vol 117. 2012-10-10. PMID:22617041. |
the selective serotonin reuptake inhibitors citalopram, sertraline, paroxetine, fluvoxamine and fluoxetine have been investigated in 10 l anaerobic lab-scale digesters with continuous stirring and mesophilic conditions at 37 °c to investigate whether they would be reduced or accumulated in sewage sludge depending on whether the bacteria present were able to use the ssris as a carbon source or not. |
2012-10-10 |
2023-08-12 |
Not clear |
| R S Lesser, J L Walters, R Khan, R Pebenito, S Kle. Improvement of Neuropsychiatric Lupus with Addition of SSRI Antidepressant/Antipsychotic Therapy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. vol 3. issue 5. 2012-10-02. PMID:19078206. |
within 7 to 10 days of initiation of paroxetine, a selective serotonin reuptake inhibitor (ssri) and fluphenazine, an antipsychotic agent, the patient's neurovegetative symptoms of depression improved and suicidality remitted. |
2012-10-02 |
2023-08-12 |
Not clear |
| S M Dursun, J G Burke, F Nielsen, A Mlynik-Szmid, M A Revele. Ssri-related toxic serotonin syndrome: improvement by discontinuation of treatment and propranolol. European psychiatry : the journal of the Association of European Psychiatrists. vol 12. issue 6. 2012-10-02. PMID:19698545. |
we report three cases in which toxic serotonin syndrome developed in relation to three different selective serotonin reuptake inhibitors (ssri) (ie, fluoxetine, sertraline, paroxetine), and which all responded to the discontinuation of the ssri and also to an additional propranolol treatment. |
2012-10-02 |
2023-08-12 |
Not clear |
| J Ballenge. New treatments for panic. European psychiatry : the journal of the Association of European Psychiatrists. vol 13 Suppl 2. 2012-10-02. PMID:19698677. |
recently, paroxetine became the first selective serotonin reuptake inhibitor to receive approval and licensing for panic disorder. |
2012-10-02 |
2023-08-12 |
Not clear |
| M B Assie, M Charveron, M Brile. In vivo [(3)H]ketanserin binding: effect of modifying synaptic serotonin levels. Neurochemistry international. vol 12. issue 1. 2012-10-02. PMID:20501207. |
on the other hand, indirect agonists such as the monoamine oxidase inhibitors, pargyline and niamide, the serotonin uptake blockers, paroxetine and midalcipran, the serotonin releasers, p-chloroamphetamine and h75/12 and the serotonin precursor, 5-hydroxytryptophan had no effect on [(3)h]ketanserin binding in vivo. |
2012-10-02 |
2023-08-12 |
mouse |
| M Gobbi, L Cervo, C Taddei, T Mennin. Autoradiographic localization of [(3)H]paroxetine specific binding in the rat brain. Neurochemistry international. vol 16. issue 3. 2012-10-02. PMID:20504564. |
specific binding of [(3)h]paroxetine, a selective serotonin uptake inhibitor, has recently been described. |
2012-10-02 |
2023-08-12 |
rat |
| M Gobbi, L Cervo, C Taddei, T Mennin. Autoradiographic localization of [(3)H]paroxetine specific binding in the rat brain. Neurochemistry international. vol 16. issue 3. 2012-10-02. PMID:20504564. |
these data indicate that [(3)h]paroxetine binding sites are mainly localized on serotonin nerve terminals even if it seems that they cannot always be directly correlated to 5-ht uptake. |
2012-10-02 |
2023-08-12 |
rat |
| S Bawa, M C Scrutto. Relationship Between the Systems Responsible for Uptake of 5-hydroxytryptamine and of Noradrenaline by Human Blood Platelets. Platelets. vol 6. issue 4. 2012-10-02. PMID:21043727. |
it is distinct from the uptake system responsible for 5-hydroxytryptamine transport into the platelet since the selective inhibitors of the platelet uptake system for 5-hydroxytryptamine (citalopram, paroxetine) wer from those for the uptake system for noradrenaline (normetanephrine, methylisoprenaline). |
2012-10-02 |
2023-08-12 |
human |
| C A Marsden, P Tyrer, P Casey, N Seivewrigh. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159137. |
changes in human whole blood 5-hydroxytryptamine (5-ht) and platelet 5-ht uptake during treatment with paroxetine, a selective 5-ht uptake inhibitor. |
2012-10-02 |
2023-08-12 |
human |
| C A Marsden, P Tyrer, P Casey, N Seivewrigh. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159137. |
the remaining three patients showed a variable response both in terms of whole blood 5-ht and platelet uptake during paroxetine treatment. |
2012-10-02 |
2023-08-12 |
human |
| C A Marsden, P Tyrer, P Casey, N Seivewrigh. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159137. |
there was no significant correlation between the change in blood 5-ht and hamilton score during paroxetine treatment. |
2012-10-02 |
2023-08-12 |
human |
| P Tyrer, C A Marsden, P Casey, N Seivewrigh. Clinical efficacy of paroxetine in resistant depression. Journal of psychopharmacology (Oxford, England). vol 1. issue 4. 2012-10-02. PMID:22159138. |
the antidepressant effects of a specific reuptake inhibitor of 5-hydroxytryptamine (5-ht), paroxetine, were tested in 24 patients with resistant depression who had failed to respond to conventional antidepressants after at least 4 weeks of treatment. |
2012-10-02 |
2023-08-12 |
Not clear |
| A Andersson, A Eriksson, J Marcusso. Unaltered number of brain serotonin uptake sites in suicide victims. Journal of psychopharmacology (Oxford, England). vol 6. issue 4. 2012-10-02. PMID:22291399. |
the 5-ht uptake sites were studied with [(3)h ] paroxetine as radioligand in frontal cortex, cingulate cortex and hypothalamus from a control group (n=22) and a group of suicide victims (n = 19). |
2012-10-02 |
2023-08-12 |
Not clear |
| b' P Favr\\xc3\\xa. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram]. L\'Encephale. vol 38. issue 1. 2012-09-06. PMID:22381728.' |
these analyses are in favor of a superior efficacy and tolerability of long-term escitalopram treatment (10 to 20mg/day) compared with active controls, including selective serotonin re-uptake inhibitors (ssris) (paroxetine, citalopram, bupropion, fluoxetine, fluvoxamine, sertraline), serotonin/noradrenaline reuptake inhibitors (snris) (venlafaxine, milnacipran and duloxetine) and noradrenergic and specific serotonergic antidepressants (nassas) (mirtazapine). |
2012-09-06 |
2023-08-12 |
Not clear |
| Chang-Gi Hur, Eun-Jin Kim, Seong-Keun Cho, Young-Woo Cho, Sook-Young Yoon, Hyun-Min Tak, Chang-Woon Kim, Changyong Choe, Jaehee Han, Dawon Kan. K(+) efflux through two-pore domain K(+) channels is required for mouse embryonic development. Reproduction (Cambridge, England). vol 143. issue 5. 2012-08-30. PMID:22419831. |
voltage-dependent k(+) channel blockers, such as tetraethylammonium and bacl(2), had no effect on embryonic development to the blastocyst stage, whereas k(2p) channel blockers, such as quinine, selective serotonin reuptake inhibitors (fluoxetine, paroxetine, and citalopram), gadolinium trichloride, anandamide, ruthenium red, and zinc chloride, significantly decreased blastocyst formation (p<0.05). |
2012-08-30 |
2023-08-12 |
mouse |
| Fatih Canan, Ugur Korkmaz, Emel Kocer, Elif Onder, Salih Yildirim, Ahmet Ataogl. Serotonin syndrome with paroxetine overdose: a case report. Primary care companion to the Journal of clinical psychiatry. vol 10. issue 2. 2012-08-23. PMID:18458731. |
serotonin syndrome with paroxetine overdose: a case report. |
2012-08-23 |
2023-08-12 |
Not clear |
| Katsumasa Muneoka, Yukihiko Shirayama, Katsushi Kon, Masaharu Kawabe, Sho Kimur. Delayed-onset obsessive-compulsive symptoms after brain infarctions treated with paroxetine. Clinical neuropharmacology. vol 34. issue 6. 2012-08-20. PMID:22104637. |
her obsessive-compulsive symptoms relating to words were successfully treated with a serotonin selective reuptake inhibitor, paroxetine, at the dose of 40 mg/d. |
2012-08-20 |
2023-08-12 |
Not clear |
| Suneeta Gollapudy, Vikram Kumar, M Saeed Dhame. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. Journal of clinical anesthesia. vol 24. issue 3. 2012-08-15. PMID:22537574. |
a case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. |
2012-08-15 |
2023-08-12 |
Not clear |
| Kunie Nakajima, Hideaki Obata, Nobuhisa Iriuchijima, Shigeru Sait. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain. vol 153. issue 5. 2012-08-13. PMID:22424692. |
in microdialysis studies, na and 5-ht concentrations in the spinal dorsal horn were increased after injection of either milnacipran or paroxetine, and only na was increased after maprotiline. |
2012-08-13 |
2023-08-12 |
rat |
| Victoria Samanidou, Kristallenia Pantazidou, Leda Kovatsi, Samuel Njau, Aristidis Livano. A simple HPLC method for the simultaneous determination of two selective serotonin reuptake inhibitors and two serotonin-norepinephrine reuptake inhibitors in hair, nail clippings, and cerebrospinal fluid. Journal of separation science. vol 35. issue 7. 2012-08-08. PMID:22532352. |
a novel and simple high-performance liquid chromatography method has been developed for the simultaneous determination of two selective serotonin reuptake inhibitors (fluoxetine and paroxetine) and two serotonin-norepinephrine reuptake inhibitors (venlafaxine and duloxetine) in alternative samples of toxicological interest such as hair, nail clippings, and cerebrospinal fluid (csf). |
2012-08-08 |
2023-08-12 |
Not clear |